{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:01:03Z","timestamp":1788818463788,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,19]],"date-time":"2027-02-19T00:00:00Z","timestamp":1802995200000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100018071","name":"Knight Cancer Institute, Oregon Health and Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006668","name":"Oregon Health and Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["P30 CA069533"],"award-info":[{"award-number":["P30 CA069533"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jcyt.2025.102005","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:18:52Z","timestamp":1763637532000},"page":"102005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies"],"prefix":"10.1016","volume":"28","author":[{"given":"Yun","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikayla K.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah J.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krislynd","family":"Estalilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Kaempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9762-8069","authenticated-orcid":false,"given":"Arpita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-8745","authenticated-orcid":false,"given":"Gabrielle","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-3167","authenticated-orcid":false,"given":"Laura F.","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.102005_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-78580-6_1","article-title":"Principles and overview of allogeneic hematopoietic stem cell transplantation","volume":"144","author":"Giralt","year":"2009","journal-title":"Cancer Treat Res"},{"issue":"4","key":"10.1016\/j.jcyt.2025.102005_bib0002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1744-313X.2012.01101.x","article-title":"ABO-incompatible organ transplantation","volume":"39","author":"Subramanian","year":"2012","journal-title":"Int J Immunogenet"},{"issue":"5","key":"10.1016\/j.jcyt.2025.102005_bib0003","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.20.01771","article-title":"Optimizing donor choice and GVHD prophylaxis in allogeneic hematopoietic cell transplantation","volume":"39","author":"Holtan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.102005_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000441507","article-title":"ABO-mismatched allogeneic hematopoietic stem cell transplantation","volume":"43","author":"Worel","year":"2016","journal-title":"Transfus Med Hemother"},{"issue":"4","key":"10.1016\/j.jcyt.2025.102005_bib0005","first-page":"322","article-title":"ABO blood grouping mismatch in hematopoietic stem cell transplantation and clinical guides","volume":"12","author":"Shokrgozar","year":"2018","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"4","key":"10.1016\/j.jcyt.2025.102005_bib0006","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bmt.1703135","article-title":"Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs","volume":"28","author":"Rowley","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jcyt.2025.102005_bib0007","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1046\/j.1537-2995.2002.00209.x","article-title":"Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning","volume":"42","author":"Worel","year":"2002","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.jcyt.2025.102005_bib0008","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1700641","article-title":"Rapid engraftment after allogeneic ABO-incompatible peripheral blood progenitor cell transplantation complicated by severe hemolysis","volume":"19","author":"Bornhauser","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2025.102005_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1537-2995.2000.40050543.x","article-title":"Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems","volume":"40","author":"Worel","year":"2000","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.jcyt.2025.102005_bib0010","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood.V98.6.1687","article-title":"Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation","volume":"98","author":"Bolan","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jcyt.2025.102005_bib0011","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bbmt.2005.07.015","article-title":"ABO blood group barrier in allogeneic bone marrow transplantation revisited","volume":"11","author":"Seebach","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jcyt.2025.102005_bib0012","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.12933","article-title":"Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program","volume":"93","author":"Kimura","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jcyt.2025.102005_bib0013","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.exphem.2008.01.017","article-title":"Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"36","author":"Michallet","year":"2008","journal-title":"Exp Hematol"},{"issue":"11","key":"10.1016\/j.jcyt.2025.102005_bib0014","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1537-2995.2004.04106.x","article-title":"Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning","volume":"44","author":"Canals","year":"2004","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.jcyt.2025.102005_bib0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbmt.2008.01.003","article-title":"ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients","volume":"14","author":"Resnick","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2025.102005_bib0016","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbmt.2013.11.011","article-title":"Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Watz","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2025.102005_bib0017","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2025.102005_bib0018","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2025.102005_bib0019","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","article-title":"Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide","volume":"4","author":"DeZern","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jcyt.2025.102005_bib0020","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.jcyt.2025.102005_bib0021","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bolanos-Meade","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jcyt.2025.102005_bib0022","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jcyt.2025.102005_bib0023","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2025.102005_bib0024","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jcyt.2025.102005_bib0025","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.jcyt.2025.102005_bib0026","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jcyt.2025.102005_bib0027","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","article-title":"Clinical guide to ABO-incompatible allogeneic stem cell transplantation","volume":"19","author":"Booth","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"10.1016\/j.jcyt.2025.102005_bib0028","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jcyt.2025.102005_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"issue":"4","key":"10.1016\/j.jcyt.2025.102005_bib0030","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ajh.26834","article-title":"Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia","volume":"98","author":"Guru Murthy","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2025.102005_bib0031","series-title":"Blood Groups and Red Cell Antigens","author":"Dean","year":"2005"},{"issue":"6","key":"10.1016\/j.jcyt.2025.102005_bib0032","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/00007890-198806000-00018","article-title":"ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation","volume":"45","author":"Bacigalupo","year":"1988","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.jcyt.2025.102005_bib0033","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.bbmt.2009.07.002","article-title":"Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients","volume":"15","author":"Ludajic","year":"2009","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"5","key":"10.1016\/j.jcyt.2025.102005_bib0034","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/trf.12466","article-title":"Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?","volume":"54","author":"Gutierrez-Aguirre","year":"2014","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.jcyt.2025.102005_bib0035","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V96.3.1150","article-title":"Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect","volume":"96","author":"Mielcarek","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2025.102005_bib0036","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2017.02.009","article-title":"Donor-to-recipient ABO mismatch does not impact outcomes of allogeneic hematopoietic cell transplantation regardless of graft source","volume":"23","author":"Damodar","year":"2017","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jcyt.2025.102005_bib0037","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-022-01287-3","article-title":"Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.102005_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.01.009","article-title":"Impact of post-transplantation cyclophosphamide on transfusion requirements in HLA-matched sibling peripheral blood stem cell transplantation","volume":"29","author":"Marco-Ayala","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jcyt.2025.102005_bib0039","doi-asserted-by":"crossref","first-page":"576.e1","DOI":"10.1016\/j.jtct.2023.06.008","article-title":"Phase II Study of Myeloablative 7-8\/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil","volume":"29","author":"Jurdi","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"28","key":"10.1016\/j.jcyt.2025.102005_bib0040","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","volume":"42","author":"Shaffer","year":"2024","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.jcyt.2025.102005_bib0041","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41409-025-02580-8","article-title":"The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT","volume":"60","author":"Guven","year":"2025","journal-title":"Bone marrow transplantation"},{"issue":"4","key":"10.1016\/j.jcyt.2025.102005_bib0042","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1365-2141.2003.04128.x","article-title":"Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation","volume":"120","author":"Lee","year":"2003","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jcyt.2025.102005_bib0043","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.bbmt.2010.03.021","article-title":"Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source","volume":"16","author":"Blin","year":"2010","journal-title":"Biology of Blood And Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"2","key":"10.1016\/j.jcyt.2025.102005_bib0044","first-page":"S77","article-title":"Impact of ABO Compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): ptcy impacts platelet engraftment, independent of ABO compatibility","volume":"30","author":"Murphy YY","year":"2024","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy."}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:57:52Z","timestamp":1773392272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925009004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1465324925009004"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102005"}}